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Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for
invasive GBS disease was conducted in four states during 1996–2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1%
(2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and
vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P<
.001). Clindamycin resistance increased from 10.5% to 15.0% (X2 for trend 12.70; P<. 001); inducible clindamycin resistance was
associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X2 for trend 55.46; P<. 001). While
GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing
concern.
Copyright © 2008 Mei L. Castor et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Early-onset group B Streptococcal (GBS) infection, occur-
ring in the ﬁrst 7 days of life, is a leading cause of invasive
bacterial infection among newborns and generally results
fromverticaltransmissionofGBSfromcolonizedmothersto
their infants. Neonatal infection is commonly characterized
by bacteremia, pneumonia, and meningitis; mortality from
early-onset disease is estimated at 5%. GBS disease among
pregnant women manifests as urinary tract infections, bac-
teremia, chorioamnionitis, endometritis, or septic abortions
[1]. Among non-pregnant adults, GBS disease typically
occurs among older or immunocompromised persons.
In the 1990s, the incidence of early-onset neonatal GBS
disease declined dramatically after widespread implementa-
tion of intrapartum antibiotic prophylaxis (IAP). Revisions
to IAP guidelines in 2002 included universal GBS screening
of pregnant women with vaginal and rectal cultures at2 Infectious Diseases in Obstetrics and Gynecology
35–37 weeks’ gestation, with IAP given to those with
positive cultures. Susceptibility testing for erythromycin and
clindamycin of GBS isolates is recommended for colonized
women who are thought to be at high risk for anaphylaxis to
penicillin or ampicillin. Cefazolin is recommended for those
who cannot take penicillin but are at low risk for anaphylaxis
[2].
Publications from the United States and Canada report
clindamycin resistance (3%–21%) and erythromycin resis-
tance (5%–29%) in GBS isolates [3–8]. Alteration of the
erythromycin-binding site on the 50S ribosomal RNA
subunit, conferred by the erm gene, and active eﬄux of
the erythromycin, conferred by the mef gene, are the
most common macrolide resistance mechanisms in beta-
hemolytic streptococci [9]. The erm gene confers resis-
tance to macrolides, lincosamides, and streptogramin B-type
antibiotics (MLSB) and may be expressed constitutively or
it may be inducible. The mef gene confers resistance only
to macrolide antibiotics, the M phenotype. The inducible
MLSB phenotype may be detected in the laboratory by
a disk approximation method (D-test), which involves
placement of an erythromycin and a clindamycin disk in
close proximity on the surface of an agar plate. Clinical
and Laboratory Standards Institute (CLSI) guidelines for
antimicrobialsusceptibilitytestingnowincludeamethodfor
performing the D-test on beta-hemolytic streptococci [10].
Serotype distribution in invasive GBS disease is of inter-
est in determining potential vaccine composition. Serotype
III has a high association with late-onset neonatal disease,
speciﬁcally meningitis. Serotype V has emerged as a more
frequent serotype in recent years [11]. Other common
serotypes include Ia and II.
We analyzed GBS surveillance data from four distinct US
sites to understand serotype and antimicrobial susceptibility
patterns in invasive isolates from perinatal (pregnant and
neonatal cases) and non-pregnant adult populations.
2. METHODS
Invasive GBS isolate data regarding antimicrobial suscep-
tibility, serotype, and epidemiologic data were collected
from selected counties in four states (Georgia, Minnesota,
New York, and Oregon); all participated in the Centers for
Disease Control and Prevention’s (CDC) Active Bacterial
Core surveillance (ABCs) system of the Emerging Infections
Program network for 1996–2003. Georgia’s initial surveil-
lance area of eight counties in the Atlanta area expanded
in 1997 to 20 counties. New York’s initial surveillance area
of seven counties in 1997 expanded to 15 counties in
2000 (seven-county Rochester area and eight-county Albany
area). Oregon’s three-county and Minnesota’s statewide
surveillanceareasremainedunchangedthroughoutthestudy
period. Total surveillance populations ranged from 8.7
million in 1996 to 13.2 million in 2003. By state, 2003
surveillance populations were 4.5 million in Georgia, 5
million in Minnesota, 2.1 million in New York, and 1.5
million in Oregon.
A case of invasive GBS was deﬁned by bacterial isolation
from a normally sterile site in a surveillance area resident.
GBS isolation from amniotic ﬂuid or placentas was included
when fetal demise occurred. Early-onset neonatal cases were
classiﬁed by a ﬁrst positive culture on days 0–6 of life and
late-onset at 7–89 days of life. Maternal cases were those
identiﬁed during the antepartum or postpartum periods
(30 days after a delivery or miscarriage). The case-ﬁnding
methodology used for the ABCs system has been previously
described [12]. Laboratory audits are performed every 6
months to capture any missed cases. Antimicrobial suscepti-
bility testing was performed at the Minnesota Department of
Health (MDH) laboratory or CDC laboratories. Serotyping
of Minnesota isolates was performed at the University of
Minnesota and CDC, and isolates from other geographic
sites were tested at CDC. Lanceﬁeld immunoprecipitation
techniques were used for serotyping. Antimicrobial suscep-
tibility testing was performed using broth microdilution in
microtiter plates containing cation-adjusted Mueller Hinton
broth with 3% lysed horse blood (PML Microbiologicals,
Wilsonville, Ore) with CLSI susceptibility deﬁnitions used
when available.
T h ec o n s t i t u t i v e( c )M L S B phenotype was inferred
from broth microdilution MIC data. Isolates found to
be erythromycin-resistant and clindamycin-susceptible were
evaluated for inducible (i) clindamycin resistance using the
double disk diﬀusion (D-test) method with clindamycin
(2μg) and erythromycin (15μg) disks (Becton Dickinson
DiagnosticSystems,Sparks,Md)placed15mmapart.Strains
that remained clindamycin-susceptible (those that did not
have ﬂattening of the susceptibility zone adjacent to the ery-
thromycin disk) were determined to be of the M phenotype.
PCRwasusedtodetectthepresenceofthemostcommon
macrolide resistance determinants in all isolates with an
Mo ri M L S B phenotype. Testing was also done on a small
subset of isolates with a cMLSB resistance phenotype. PCR
for detection of ermA, ermB, and ermCw a sp e r f o r m e da s
described by Sutcliﬀe et al. [13]. Detection of ermTR and mef
(the primers amplify both mefAa n dmefE) was performed
using primers designed at MDH. The PCR reactions for
ermTR and mefA/E contained 10mM Tris HCl, 50mM
KCl, 1.5mM MgCl2,1μM forward and reverse primers, and
2μlo ft e m p l a t eD N Ai nat o t a lv o l u m eo f5 0 μL. Primers
used for the ampliﬁcation of ermTR, a subclass of ermA
[14], were TR-322U, 5 -GGGTCAGGAAAAGGACAT-3 ,
and TR619L, 5 -CCTAAAGCTCGTTGGGTATT-3 .P r i m e r s
used for the ampliﬁcation of mefA/E were mef-3301U, 5 -
AGGGCAAGCAGTATCATTAATCA-3 , and mef-3673L, 5 -
CTGCAAAGACTGACTATAGCCT-3 . Optimum annealing
temperatures for ermTR and mefPCR were 56◦Ca n d5 5 ◦C,
respectively. PCR products were resolved on a 2% agarose
g e l .T h ee x p e c t e df r a g m e n ts i z ef o rermTR was 317bp and
for mef was 394bp.
SAS (version 9.1) was used for frequency and univariate
analysis.TrendanalyseswereperformedwithEpiInfo(CDC,
Atlanta, Ga) statistical software (version 6.04c). Chi-square
calculations were used to compare continuous variables,
with Yates continuity-corrected chi-square used to compare
categorical variables. The Mantel-Haenszel chi-square test
for trend was used to examine trends across the study
period; the Mantel-Haenszel extended test adjusted forMei L. Castor et al. 3
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Figure 1: Clindamycin and erythromycin resistance among inva-
sive Group B streptococci isolates by year (n = 2937 isolates).
possible confounders. An alpha ≤0.05-signiﬁcance level was
used.
3. RESULTS
Of the 5373 patients, 71% had isolates submitted to a public
health laboratory and the antimicrobial susceptibility testing
was performed on 77.1% (2937). The plurality of isolates
were from Minnesota (46.8% or 1375), followed by Georgia
(26.1% or 768), New York (16.9% or 496), and Oregon
(10.2% or 300). The perinatal category comprised 24.4%
(1311) of the total sample with 12.5% (671) early-onset,
7.9%(424)late-onset,and4.0%(216)maternalpatients.The
non-pregnant adult category accounted for 73.5% (3951) of
the total.
All 2937 isolates were susceptible to penicillin, ampi-
cillin, cefotaxime, and vancomycin. Although no CLSI
breakpoints existed for the ﬁrst-generation cephalosporins
(cephalothin and cefazolin), all the isolates tested had
minimum inhibitory concentrations (MICs) ≤ 0.5mcg/mL
and were, therefore, considered susceptible. Similarly, no
breakpoints existed for cefuroxime and cefoxitin. All 1201
Minnesota isolates tested for cefuroxime susceptibility had
MICs ≤ 0.12mcg/mL and were, therefore, considered sus-
ceptible. Of 2937 isolates tested for cefoxitin susceptibility,
36.7% (1078) had MICs ≤ 2mcg/mL; 62.5% (1835) had
MICs = 4mcg/mL; 0.7% (22) had MICs = 8mcg/mL;and
0.1% (4) had MICs ≥ 16mcg/mL.
Clindamycin resistance was identiﬁed in 12.7% (374),
and erythromycin resistance was identiﬁed in 25.6% (752) of
isolatestested. During thestudyperiod, asigniﬁcantincrease
was observed in the proportion of isolates resistant to each of
theseantibiotic(forclindamycin10.5%in1996versus15.0%
in 2003, X2 for trend = 12.70, P<. 001, for erythromycin
15.8% in 1996 versus 32.8% in 2003, X2 for trend = 55.46,
P<. 001) (see Figure 1). Concurrent resistance to both
clindamycin and erythromycin was identiﬁed in 12.6% (370)
of isolates tested.
Signiﬁcant diﬀerences were identiﬁed between Min-
nesota and New York isolates in clindamycin resistance
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Figure 2: Clindamycin and erythromycin resistance among inva-
sive Group B streptococci isolates by state (n = 2937 isolates).
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Figure 3: Resistance invasive Group B streptococci isolates among
pregnant women and newborns (perinatal) and non-pregnant
adults (n = 2887 isolates).
(13.2% versus 9.3%, P = .03) and erythromycin resistance
(24.5% and 31.4%, P<. 01). Georgia isolates were more
likely to be resistant to clindamycin than New York isolates
(15.1% and 9.3%, P = .02), but Georgia isolates were less
likely to be resistant to erythromycin than to New York
isolates (26.3% and 31.4%, P = .04) (see Figure 2).
The proportion of isolates resistant to clindamycin and
erythromycin did not diﬀer signiﬁcantly between the peri-
natal and non-pregnant adult patient groups (see Figure 3).
Within the perinatal group, the overall clindamycin resis-
tance was 13.1%, with no signiﬁcant changes between
the early-onset (14.9%), late-onset (10.3%), and maternal
populations (13.7%). Likewise, no signiﬁcant diﬀerences in
erythromycin resistance levels were identiﬁed between the
diﬀerent perinatal groups (21.9% overall; 21.2% for early-
onset, 22.1% for late-onset, and 23.9% maternal).
Serotyping was performed on 64.6% (3471) of isolates.
The largest proportion was from Georgia (34.7%), followed
by Minnesota (28.5%), New York (23.9%), and Oregon
(12.9%). Table 1 illustrates the serotypes identiﬁed during
thestudyperiod,withpredominantserotypegroupsbeingV,
Ia, and III. The proportion of isolates with serotype III was
observed to have a signiﬁcant downward trend (X2 trend =
38.8; P<. 001) during the study period from 25% in 19964 Infectious Diseases in Obstetrics and Gynecology
Table 1: Distribution of serotypes and resistance to erythromycin and clindamycin among invasive group B streptococcus isolates.
Serotyped isolates with susceptibility results
Serotype Serotyped isolates Total Erythromycin-resistant Clindamycin-resistant
no. (%)∗ no. (%) no. (%)
(n = 3471) (n = 2551) (n = 669) (n = 301)
Ia, Ia/c 835 (24.1) 573 112 (17) 13 (4)
Ib, Ib/c 296 (8.5) 231 37 (6) 10 (3)
II, II/c 357 (10.3) 255 68 (10) 46 (15)
III, III/c 680 (19.6) 496 78 (12) 26 (9)
V, V/c 951 (27.4) 695 293 (44) 166 (55)
NT, NTc 247 (7.1) 175 65 (10) 30 (10)
Other∗∗ 105 (3.0) 120 16 (2) 10 (3)
∗of isolates serotyped.
∗∗IV, IV/c, VI, VI/c, and VIII.
to 17% in 2003; no such trend was observed with the other
predominant serotypes.
The most common serotype in the perinatal population
was serotype III (37.0%; 351/948). This was signiﬁcantly
diﬀerent than for non-pregnant adults in which serotype V
was most common (31.5%; P<. 001).
Both susceptibility and serotyping testing were per-
formed on 2551 isolates. The largest proportion of these
isolates were from Minnesota (38.9%), followed by Georgia
(30.1%), New York (19.4%), and Oregon (11.8%). Clin-
damycin resistance was 3.9 times (P<. 001) more likely to
occur in serotype V isolates (25.8%) than in other serotypes
(8.2%). In addition, erythromycin resistance was 2.9 times
(P<. 001)morelikelytooccurinserotypeVisolates(42.2%)
than in other serotypes (20.2%). Subanalysis within the
diﬀerent disease categories indicated a signiﬁcant association
among clindamycin or erythromycin resistance and early-
onset (P<. 001), late-onset (P<. 001), and non-pregnant
adult populations (P<. 001). No such association was
observed among the maternal population.
Three hundred ﬁfty-ﬁve erythromycin-resistant (47%)
isolates were further characterized. Seventy-eight isolates
(22%) had an M phenotype and all of these isolates
contained mef only. Fifty-two percent (184/355) were
constitutively resistant to clindamycin (cMLS). Seventeen
were further tested. Ten were positive for ermB and seven
contained ermTR; one isolate had both mef and ermTR and
one isolate had both mef and ermB. Twenty-ﬁve percent of
isolates had inducible clindamycin resistance (iMLS). All of
the iMLS isolates were tested for resistance genes; 83 (92%)
contained ermTR, 1 isolate contained ermB, and 6 isolates
were negative for ermTR and ermB.
Univariate analysis was conducted comparing resistance
genes to serotypes. Serotype V was associated with a lower
proportion of mef positive isolates compared to all other
serotypes (P<. 01). In contrast, serotypes Ia, Ia/c, and III
were associated with a higher proportion of mef-positive
isolates compared to all other serotypes (all P values <.01).
Serotype V had a higher proportion of isolates with ermTR,
73% of 37 tested compared with 29% among all other
serotypes (P<. 01).
4. CONCLUSIONS
This study demonstrated the prevalence of resistance to
antibiotics commonly used for prophylaxis or treatment
of GBS infections among a large, multisite, collection of
isolates. We found that all invasive GBS isolates tested
were susceptible to penicillin and ampicillin, the ﬁrst-line
agents recommended for IAP and to cefazolin and van-
comycin, second-line agents recommended for use among
IAP candidates who report penicillin allergies. In contrast,
GBS resistance to clindamycin (12.7%) and erythromycin
(25.6%) was common. Subanalysis of early-onset patient
isolates indicated clindamycin resistance at 14.9% and ery-
thromycin resistance at 21.2%. These ﬁndings are consistent
with previous reports in the literature [3–8]a n ds u p p o r t
the 2002 guidelines requiring susceptibility testing of isolates
from IAP candidates with penicillin allergy. Of note, because
of reports of subtherapeutic concentrations in amniotic
ﬂuid and fetal serum, certain healthcare specialists do not
recommend using erythromycin for IAP [15]. Clinicians
should be aware of the potential for MLS resistance when
determining empiric regimens that target GBS disease.
We found an overall concordance between the MLS phe-
notype and resistance genotype. D-testing revealed inducible
clindamycin resistance in erm-containing GBS isolates and
also detected resistance in isolates with determinants not
identiﬁable by existing PCR methods. Our ﬁndings sup-
port the 2002 CDC guideline to test both erythromycin
and clindamycin susceptibilities if one of these agents is
being considered. Further D-testing should be done if
erythromycin resistance and clindamycin susceptibility are
found. Rarely, clindamycin resistance without concurrent
erythromycin resistance can be observed; this has been
associated with the linBg e n e[ 9]. Minimal diﬀerences were
identiﬁed in clindamycin and erythromycin resistance levels
across the four geographic areas as well as between the
perinatal and non-pregnant adult groups. This indicates that
GBS-resistancepatternsmightreﬂectmoreofanationalthan
a regional phenomenon.
We noted high cefoxitin MICs to GBS among our
GBS isolates. This is not surprising because cefoxitin is aMei L. Castor et al. 5
cefomycin, a class of antibiotics which typically provides
optimal coverage for anaerobes but lacks adequate activity
against gram-positive bacteria. Cefoxitin is likely to provide
suboptimal GBS coverage for chorioamnionitis and postpar-
tum endometritis.
The predominant GBS serotypes were Ia, III, and V,
which together comprised approximately 70% of all isolates
serotyped. The predominance of these serotypes among
the perinatal population is consistent with reports in the
literature [4, 11] as is the association between serotype V
and erythromycin or clindamycin resistance [4, 7]. We found
an association of serotype V with the erm genotype which
confers resistance to both erythromycin and clindamycin.
This study has several limitations, including variability
in surveillance periods for isolates collected, a varying
proportion of cases with isolate collection and susceptibil-
ity and serotyping results, and diﬀerences in surveillance
populations. However, the ABCs surveillance system is an
active, multiregional, and population-based system, and
the methods to determine susceptibilities and serotyping
were standardized. Continued surveillance of invasive GBS
disease including susceptibility and serotype determinations
will impact plans for prevention including IAP agents and
vaccine design.
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